WDHA syndrome is a rare condition defined by three hallmark features: watery diarrhea, hypokalemia (dangerously low potassium), and achlorhydria (absent or near-absent stomach acid production). It is caused by tumors that secrete massive amounts of vasoactive intestinal peptide, or VIP, and is sometimes called Verner-Morrison syndrome after the two physicians who first described it in 1958, or “pancreatic cholera” because the diarrhea can mimic the fluid losses seen in cholera.1PubMed. VIPoma The syndrome is exceedingly uncommon, but it can become life-threatening within days if the fluid and electrolyte losses are not aggressively managed.
What VIP Does to the Gut
Vasoactive intestinal peptide is a hormone your body normally produces in small amounts. It relaxes smooth muscle, dilates blood vessels, and stimulates the intestines to secrete water and electrolytes. In tiny quantities, this is useful. When a tumor starts pumping VIP into the bloodstream at ten or more times the normal level, the intestines essentially open the floodgates. Plasma VIP concentrations in affected patients have been measured at 100 to 200 pmol/L, compared to a normal level below 20 pmol/L.2Gastroenterology. Vasoactive intestinal peptide-secreting carcinoma of the esophagus
The resulting diarrhea is secretory, meaning the gut is actively pumping fluid into the intestinal lumen rather than simply failing to absorb it. Stool volumes can exceed seven liters per day in typical cases and have been documented as high as 15 to 20 liters per day in extreme ones.3PubMed Central. Pancreatic VIPoma as a Differential Diagnosis in Chronic Pediatric Diarrhea: A Case Report and Review of the Literature4Gastroenterology. Vasoactive intestinal peptide-secreting carcinoma of the esophagus That volume of fluid loss carries with it enormous quantities of potassium and bicarbonate, which is why the syndrome’s other two defining features, low potassium and suppressed gastric acid, follow so predictably. The potassium drain alone can become critical: one case report documented potassium replacement requirements exceeding 1,000 mmol per day just to keep the patient alive.5Gastroenterology. Vasoactive intestinal peptide-secreting carcinoma of the esophagus
Beyond the Big Three Symptoms
The watery diarrhea, low potassium, and achlorhydria get top billing, but VIP excess triggers a broader metabolic cascade. The massive bicarbonate loss through stool frequently leads to severe hyperchloremic metabolic acidosis, meaning the blood becomes dangerously acidic.6PubMed Central. Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma Dehydration and rapid weight loss follow directly from the fluid volumes being lost.
VIP also stimulates glycogenolysis, the breakdown of stored glycogen in the liver, which can cause episodes of high blood sugar. And because VIP dilates blood vessels and triggers prostaglandin release, many patients experience cutaneous flushing, a red, warm flush across the skin that can be mistaken for an allergic reaction or carcinoid syndrome.7PubMed Central. Hypercalcemia as the Presenting Finding in VIPoma Hypercalcemia, or elevated blood calcium, has also been reported as a presenting feature and adds another layer to the electrolyte chaos these patients face.
One underappreciated consequence of VIP’s vasodilatory effects is hemodynamic instability. Some patients develop persistent low blood pressure or outright shock, particularly around the time of surgery. Adolescent and pediatric cases have documented severe hypotensive crises during the perioperative period.8PubMed. Perioperative Hypotensive Crisis in an Adolescent with a Pancreatic VIPoma and MEN1-Gene Variant One case report described persistent shock, flushing, and watery diarrhea from a VIP-producing pheochromocytoma that responded dramatically to octreotide.9PubMed Central. Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature
Where the Tumors Come From
Most VIPomas arise in the pancreas, specifically from non-beta islet cells.10PubMed. Radiologic and pathologic characteristics of the WDHA syndrome Historically, the syndrome was considered almost exclusively a pancreatic disease. But VIP-secreting tumors can also grow from neural crest tissue. In adults, rare cases have been linked to pheochromocytomas, adrenal tumors that normally secrete catecholamines but occasionally co-produce VIP.11PubMed Central. Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature An even more unusual case documented a VIP-secreting carcinoma originating in the esophagus, a location so unexpected that it expanded the known range of WDHA-causing tumors beyond the pancreas and sympathetic chain.12Gastroenterology. Vasoactive intestinal peptide-secreting carcinoma of the esophagus
In children, the picture looks different. Pediatric WDHA syndrome is more commonly caused by neural crest tumors such as ganglioneuroblastomas and neuroblastomas rather than pancreatic tumors. One documented case involved a ganglioneuroblastoma that was only discovered at autopsy, where the tumor tissue tested positive for VIP production.13PubMed. WDHA syndrome caused by VIP-producing ganglioneuroblastoma A French retrospective study found that fewer than one percent of patients with diagnosed neuroblastoma had clinical evidence of VIP secretion, making this an uncommon presentation of an already uncommon childhood cancer.14Hrčak / Biochemia Medica. An unusual case of neuroblastoma presenting with prolonged watery diarrhea in a pediatric patient When a child presents with persistent, unexplained watery diarrhea and electrolyte abnormalities, clinicians need to consider neural crest tumors alongside the usual gastrointestinal culprits.
Why Diagnosing WDHA Syndrome Is Harder Than It Sounds
The textbook triad of watery diarrhea, low potassium, and achlorhydria should theoretically point toward VIPoma quickly. In practice, most patients endure months or years of workup for more common causes of chronic diarrhea before anyone checks a VIP level. The syndrome’s rarity is partly to blame: sporadic VIPoma has an annual incidence of roughly one in ten million people.15PubMed. Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome Most gastroenterologists will never see a case in their career.
Even when VIP levels are checked, interpreting them is surprisingly unreliable. A recent study found that using the standard threshold of 75 pg/mL to flag a possible VIPoma yielded a positive predictive value of only about 12 percent, meaning nearly nine out of ten patients with an elevated VIP level did not have a VIPoma. The study suggested that a much higher threshold, around 442 pg/mL, was needed for statistically meaningful odds of an actual tumor, and that meaningful signal only began to emerge at levels above 200 pg/mL.16Endocrine-Related Cancer. Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma This is a significant clinical problem: a mildly elevated VIP level can send clinicians on an expensive imaging chase for a tumor that does not exist, while truly high levels may not be checked in the first place if VIPoma is not on the radar.
Once VIPoma is seriously suspected, cross-sectional imaging with CT or MRI can usually identify pancreatic tumors, which tend to be sizable by the time they cause symptoms. Functional imaging with radiolabeled somatostatin analogues can help locate tumors and metastases, particularly when planning targeted therapies.
The MEN1 Connection
A small but important subset of VIPomas occur in the context of multiple endocrine neoplasia type 1, or MEN1, an inherited syndrome that predisposes people to tumors in the parathyroid glands, the pituitary, and the pancreas. VIPomas appear in roughly five percent of MEN1 patients, a rate dramatically higher than the one-in-ten-million incidence in the general population.17PubMed. Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome
MEN1 is an autosomal dominant disorder caused by mutations in the MEN1 gene. In one case, a patient diagnosed with a VIPoma was found to carry a MEN1 mutation, and genetic testing of his two sons revealed the same mutation.18PubMed Central. VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation This means that when someone is diagnosed with a VIPoma, particularly if they are younger or have a family history of endocrine tumors, screening for MEN1 can identify relatives who need surveillance long before they develop symptoms.
The genetics are not always straightforward. One adolescent with a pancreatic VIPoma and a father who had both hyperparathyroidism and a history of gastrointestinal tumor resection was found to carry a MEN1 gene variant classified as “of uncertain significance.” The family still met the clinical diagnostic criteria for MEN1, and ongoing surveillance was recommended despite the ambiguous genetic result.19PubMed. Perioperative Hypotensive Crisis in an Adolescent with a Pancreatic VIPoma and MEN1-Gene Variant The lesson here is that clinical presentation can outweigh the genetic test: if the family history looks like MEN1, treat it as MEN1 regardless of whether the lab confirms a known pathogenic mutation.
Stabilization Comes First
The immediate priority in WDHA syndrome is keeping the patient alive, and that means aggressive fluid and electrolyte replacement. Before anyone can think about surgery or tumor-directed therapy, the dehydration, metabolic acidosis, and potassium deficit need to be corrected. Patients can require intensive care unit admission simply for the volume and complexity of their intravenous replacement needs.20PubMed Central. Pancreatic Vasoactive Intestinal Peptide-Producing Tumor as a Rare Cause of Acute Diarrhea and Severe Hypokalemia
Alongside fluid resuscitation, somatostatin analogues such as octreotide are the medical backbone of WDHA management. Octreotide works by binding to somatostatin receptors on the tumor and in the gut, suppressing VIP release and reducing intestinal secretion. In many cases, the response is rapid and dramatic. One report of a VIP-producing pheochromocytoma described all clinical symptoms, including shock and flushing, resolving swiftly after octreotide was started.21PubMed Central. Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature Somatostatin analogues also appear to slow tumor growth to some extent, making them useful both for symptom control and as a bridge to definitive treatment.22PubMed Central. Pancreatic Vasoactive Intestinal Peptide-Producing Tumor as a Rare Cause of Acute Diarrhea and Severe Hypokalemia
Surgery and Treatment of Advanced Disease
Surgical resection of the VIPoma is the treatment of choice whenever possible. In a retrospective analysis of the European Neuroendocrine Tumor Society database, surgery on the primary tumor was performed in just over half of patients, with curative intent in roughly a third.23PubMed Central. Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database Complete removal of the tumor can resolve symptoms entirely. In a series from a single institution, two out of four patients with confirmed metastatic disease had complete resolution of their diarrhea after surgical resection.24Journal of Gastrointestinal Surgery. Pancreatic VIPomas: Subject Review and One Institutional Experience
When the tumor has already spread, particularly to the liver, the treatment strategy shifts to a multimodal approach. A multicenter French series evaluated treatments for metastatic VIPoma and found that curative-intent surgery achieved antisecretory efficacy in all cases where it was possible. Somatostatin analogues alone controlled hormone-related symptoms about two-thirds of the time. Chemotherapy achieved symptom control in most patients, while transarterial liver embolization had a lower response rate. Newer targeted agents like sunitinib showed high antisecretory efficacy in a small number of patients, while everolimus was less effective at controlling symptoms.25Pancreatology. Efficacy of treatments for VIPoma: A GTE multicentric series
Peptide receptor radionuclide therapy, or PRRT, has emerged as a promising option for patients whose tumors express somatostatin receptors. This approach uses radiolabeled somatostatin analogues to deliver targeted radiation directly to tumor cells. In patients with VIPomas, PRRT has demonstrated immediate symptom control in roughly 80 percent of treated patients, with the potential to reduce both tumor size and hormone levels.26PubMed Central. Treatment options of metastatic and nonmetastatic VIPoma: a review The treatment appears to be well tolerated and offers an option for patients who are not surgical candidates or whose disease has progressed through other therapies.27PubMed Central. Vasoactive intestinal peptide secreting tumour: An overview
The overall prognosis for VIPoma patients is better than many other pancreatic malignancies, partly because these tumors tend to be relatively slow-growing neuroendocrine neoplasms rather than aggressive adenocarcinomas. One institutional series reported that three of four patients with metastatic VIPoma remained alive at follow-up, with one patient dying of progressive disease 96 months, or eight years, after surgery.28Journal of Gastrointestinal Surgery. Pancreatic VIPomas: Subject Review and One Institutional Experience An aggressive surgical approach combined with systemic and targeted therapies can extend survival meaningfully, even in advanced disease.
Life-Threatening Cardiac Risk from Potassium Loss
One aspect of WDHA syndrome that deserves particular attention is the cardiac danger posed by severe hypokalemia. Potassium is essential for normal heart rhythm, and when levels drop low enough, life-threatening arrhythmias can result. In at least one reported case, the initial presentation of a VIPoma was ventricular fibrillation, a cardiac arrest rhythm, caused by the electrolyte imbalance from undiagnosed WDHA syndrome.29PubMed. Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome This underscores why the “H” in WDHA is not a minor laboratory curiosity. Hypokalemia in this syndrome can kill before anyone thinks to look for a tumor.
Cases where the metabolic derangement becomes truly refractory, where fluid and electrolyte replacement cannot keep up with the losses, are the most feared clinical scenario. One case of a malignant VIP-secreting pheochromocytoma described an irreversible course in which massive dehydration, severe acidosis, and hypokalemia could not be controlled despite aggressive therapy.30PubMed Central. Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma These outcomes are rare but highlight why rapid recognition and treatment with octreotide matter so much.
The Burden of Chronic Secretory Diarrhea
Even when WDHA syndrome is identified and treated, patients who live with ongoing or partially controlled secretory diarrhea face a substantial quality-of-life burden. Research on patients with neuroendocrine tumors and hormone-related diarrhea has found that the frequency of bowel movements, fecal incontinence, and flushing episodes all correlate with decreased quality of life. Compared to other cancer populations and general population averages, patients with functioning neuroendocrine tumors report higher rates of depression, cognitive difficulty, fatigue, anxiety, and impaired sleep. Diarrhea has a particularly prominent adverse impact on physical, emotional, and social well-being.31PubMed Central. Management of Diarrhea in Patients With Carcinoid Syndrome
For patients with metastatic VIPoma who cannot be cured surgically, the chronic nature of these symptoms means that optimizing symptom control is not merely about comfort. It is about enabling patients to participate in daily life. The debilitating effect of uncontrolled diarrhea in these patients can be severe enough to dominate their illness experience regardless of tumor progression.32Pancreas. Differential Diagnosis of Diarrhea in Patients with Neuroendocrine Tumors The expanding toolkit of somatostatin analogues, PRRT, and targeted systemic agents has improved the picture over the past two decades, but many patients still cycle through multiple therapies searching for adequate control.
Conditions That Mimic WDHA Syndrome
Several other diagnoses can produce a clinical picture that overlaps with WDHA syndrome, and sorting them out matters because the treatments are completely different. Carcinoid syndrome, caused by serotonin-secreting neuroendocrine tumors, can produce diarrhea and flushing but usually involves different biochemical markers and the diarrhea tends to be less voluminous. Zollinger-Ellison syndrome, caused by gastrin-secreting tumors, also produces diarrhea, but gastric acid is massively overproduced rather than absent, which is the opposite of what happens in WDHA. Chronic laxative abuse, celiac disease, inflammatory bowel disease, and microscopic colitis all enter the differential for chronic watery diarrhea in practice.
In children, the differential is broader still. A child with treatment-resistant watery diarrhea and electrolyte disturbances might have a VIP-secreting neuroblastoma, but neuroblastoma far more commonly presents as an abdominal mass, bone pain, or other symptoms unrelated to VIP.33Hrčak / Biochemia Medica. An unusual case of neuroblastoma presenting with prolonged watery diarrhea in a pediatric patient The rarity of VIP secretion in neuroblastoma, fewer than one percent of cases, means it is rarely the first diagnosis considered. The key clinical clue is persistence: when diarrhea continues despite standard treatments and is accompanied by hypokalemia and metabolic acidosis, the secretory nature of the diarrhea should trigger investigation for a hormone-producing tumor, regardless of the patient’s age.